Josh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP / Rhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE - Realizing the Potential of Rapid-Acting Treatments for Depression: Key Clinical Evidence, Practical Considerati
Listen now
Description
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete NCPD/CE/AAPA information, and to apply for credit, please visit us at PeerView.com/EUC865. NCPD/CE/AAPA credit will be available until November 11, 2024. Realizing the Potential of Rapid-Acting Treatments for Depression: Key Clinical Evidence, Practical Considerations, and Best Practices for Individualized, Patient-Centered Care Optimal management of depression begins with adequate screening and early introduction of appropriate therapy. However, monoaminergic antidepressant therapies, which are currently considered the standard of care, have several limitations, such as slow therapeutic response times, suboptimal efficacy and remission rates, and adverse effects that may impact patient adherence. Recent research has focused on novel pathways involved in the etiology of depression, including glutamatergic and GABAergic modulation. For example, neuroactive steroids such as zuranolone act as positive allosteric modulators of the GABA-A receptor. In 2023, zuranolone became the first and only oral therapy to be approved for the treatment of postpartum depression. There have also been advances in glutamatergic antidepressants, with the approval of esketamine nasal spray for treatment-resistant depression in 2019 and for depression with acute suicidal ideation or behavior in 2020, as well as the approval of dextromethorphan-bupropion for the treatment of major depressive disorder in 2022. In order to help clinicians remain abreast of the latest treatment options for depression, PeerView recently held a Candid Conversations & Clinical Consults educational symposium, featuring a panel of psychiatric–mental health nursing faculty. These depression experts paired compelling, real-world case scenarios with practice-changing evidence to illustrate how to integrate novel and emerging treatments for depression into clinical practice, including strategies to identify patients who may benefit from these treatments, and how to use shared decision-making to craft individualized treatment plans. If you couldn’t watch the live event, this on-demand version is available now! Co-Chair & Moderator Josh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP The Hamilton Group Behavioral Health LLC Las Vegas, Nevada Co-Chair & Presenter Rhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE Rasmussen University Bloomington, Minnesota In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Sage Therapeutics and Biogen. Disclosure Policy PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Co-Chair/Planner Josh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Alkermes and Point of Care Network, LLC (POCN). Speaker for Myriad Neuroscience and P
More Episodes
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for...
Published 05/24/24
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit,...
Published 05/20/24